6.7.9. monitoring treatment. baseline examinations include medical history, clinical examination well baseline blood tests (psa, total testosterone level, full blood count, renal function, baseline liver function tests, alkaline phosphatase), bone scan ct chest, abdomen pelvis . use choline psma pet/ct scans progressing crpc unclear likely beneficial patients bcr hormone-naive disease. flares, psma upregulation discordant results compared psa response progression arpi described . prostate-specific antigen alone reliable enough monitoring disease activity advanced crpc since visceral metastases may develop men without rising psa . instead, pcwg2 recommends combination bone scintigraphy ct scans, psa measurements clinical benefit assessing men crpc . majority experts 2015 advanced prostate cancer consensus conference (apccc) suggested regular review repeating blood profile every two three months bone scintigraphy ct scans least every six months, even absence clinical indication . reflects agents proven os benefit potential toxicity considerable cost patients objective benefit treatment modified. apccc participants stressed treatments stopped psa progression alone. instead, least two three criteria (psa progression, radiographic progression clinical deterioration) fulfilled stop treatment. trial purposes, updated pcwg3 put weight importance documenting progression existing lesions introduced concept longer ‘clinically benefiting‘ underscore distinction first evidence progression clinical need terminate change treatment . recommendations also seem valid clinical practice outside trials.